David Kirn, CEO of 4D Molecular Therapeutics, discusses the development of their gene therapy platform and the tension between platform and product focus. He emphasizes the importance of balancing a strong platform with diverse product opportunities to decrease risk and increase success. The episode also explores fundraising, regional dynamics of biotech investment, and the benefits of a common technology stack in therapeutic development.